TRT Adjunct Therapies: What May Help, What Is Overused, and What Needs Monitoring

The best TRT adjunct is the one that addresses a defined problem. There is no universal stack that makes TRT work better for every man. Adding a medication or supplement without a clear target can create side effects, muddy laboratory results, and make it harder to tell what is helping.

Before adding anything, define the goal. Fertility, testicular function, erectile difficulty, diagnosed thyroid disease, sleep apnea, and a specific hormone-related adverse effect are different clinical problems. They should not be managed with the same add-on.

HCG may have a role when fertility or testicular function is the question

Exogenous testosterone suppresses signaling from the brain to the testes and can reduce sperm production. HCG acts at the luteinizing hormone receptor and can stimulate testicular testosterone production in selected clinical settings.

That does not make HCG a guaranteed fertility shield. The AUA and ASRM male infertility guideline states that clinicians may use HCG or other hormonal approaches in infertile men with low testosterone, but rates the supporting evidence as conditional and low quality. It also states that testosterone monotherapy should not be prescribed to men interested in current or future fertility.

The Endocrine Society raised a more specific concern in September 2026: concurrent HCG and TRT can suppress follicle-stimulating hormone, which is also necessary for sperm production, and prolonged treatment may delay recovery after therapy stops. Men who may want biological children need a fertility plan, and often a semen analysis, before relying on an adjunct.

Erectile dysfunction treatment solves a different problem than testosterone

TRT may improve sexual desire in men with confirmed testosterone deficiency, but erections also depend on blood flow, nerve function, medications, metabolic health, and psychological context.

The AUA erectile dysfunction guideline supports established erectile dysfunction treatments based on the patient's health and preferences. In men who have both testosterone deficiency and erectile dysfunction, correcting testosterone deficiency may improve the response to a phosphodiesterase type 5 inhibitor. That does not mean every man on TRT needs an erectile dysfunction medication.

Persistent erectile symptoms should prompt a cardiovascular and metabolic review. Erectile dysfunction can precede the diagnosis of vascular disease, so simply adding another hormone can miss the more important risk.

Aromatase inhibitors are not routine TRT maintenance

Some testosterone is converted to estradiol. Men need estradiol for bone, sexual, and other physiologic functions. A laboratory value outside a reference interval does not automatically require another prescription.

An aromatase inhibitor may be considered in selected situations after symptoms, examination findings, testosterone exposure, and estradiol measurement are reviewed. Routine estrogen suppression can overshoot and contribute to low libido, joint symptoms, or bone concerns.

Ask whether there is a specific symptom or diagnosis that the treatment is expected to improve, then decide how that outcome will be monitored.

Thyroid treatment belongs to diagnosed thyroid disease

Fatigue, weight change, low mood, and poor concentration can occur with both testosterone deficiency and thyroid disease. That overlap does not justify adding thyroid hormone to make TRT feel stronger.

Thyroid treatment should follow an appropriate diagnosis and a clinician-directed monitoring plan. Reverse T3 alone is not a reason to prescribe a thyroid combination. If symptoms persist despite stable testosterone exposure, the answer may be a broader medical evaluation rather than another hormone.

DHEA and pregnenolone are often added with little evidence

DHEA and pregnenolone are hormone precursors, which makes them sound like logical additions. Routine supplementation for energy, cognition, libido, or anti-aging is not well supported.

In a two-year randomized trial of DHEA or low-dose testosterone in older adults, DHEA did not produce the broad anti-aging benefits often claimed for it. These supplements can also alter hormone measurements and cause adverse effects. A low result, the assay used, symptoms, and the intended outcome all need context.

Sermorelin should be evaluated as a separate therapy

Sermorelin stimulates growth hormone release through a different hormonal pathway. High-quality trials have not established that adding it to testosterone improves fat loss, muscle, sleep, or recovery for every man.

A licensed clinician should evaluate Sermorelin on its own indications, evidence, risks, monitoring needs, and treatment goals. Combining two therapies also makes attribution harder. If sleep or recovery changes, the patient and clinician need to know which variable changed and whether the benefit is measurable.

The most useful adjunct may not be another prescription

Treating sleep apnea, reducing heavy alcohol use, managing blood pressure, improving diabetes control, resistance training, and eating enough protein can change the symptoms men often hope an adjunct will fix.

These steps are not interchangeable with treatment for diagnosed hypogonadism. They address other constraints on energy, body composition, erections, and long-term health. The FDA testosterone labeling update also makes blood pressure monitoring especially relevant during TRT.

Five questions to ask before adding an adjunct

1. What exact symptom, diagnosis, or reproductive goal are we treating?
2. What evidence supports this option for that goal?
3. Is the use approved for this indication, off-label, or based on limited evidence?
4. Which labs, symptoms, or outcomes will show whether it worked?
5. What is the stopping plan if it does not help or causes harm?

If those questions do not have clear answers, adding another therapy is likely to make the protocol more complicated without making it better.

The bottom line

TRT adjuncts are clinical tools, not automatic upgrades. HCG may be considered in a fertility-focused plan. Erectile dysfunction treatment may address a vascular problem that testosterone does not fix. Estrogen and thyroid medications require a defined indication. DHEA, pregnenolone, and Sermorelin should not be sold as routine multipliers of TRT results.

A licensed clinician can help separate the treatment goal from the marketing promise and build the smallest protocol that addresses the actual problem.

This article is for educational purposes and is not medical advice. Treatment availability, appropriateness, and prescribing decisions depend on an individual evaluation by a licensed clinician.